{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:12:56Z","timestamp":1783660376992,"version":"3.55.0"},"reference-count":170,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundacja Sanfilippo","award":["2\/2025"],"award-info":[{"award-number":["2\/2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Mucopolysaccharidoses (MPS) are severe, inherited metabolic diseases, classified among lysosomal storage diseases (LSDs). The presence of pathological variants of genes coding for enzymes involved in the degradation of glycosaminoglycans (GAGs) is a primary cause of each MPS type, and accumulation of these compounds is a characteristic feature of MPS. Depending on the kind of defective enzyme and the type of stored GAG(s), 12 classical types are distinguished, and a few other related diseases, whose classification is unclear. Although there is no fully effective cure for MPS, several kinds of therapeutic approaches have been proposed to treat these diseases, and some of them have been introduced into clinical practice. In this review article, we present and discuss very recent advances in developing various therapies for MPS, also indicating problems and limitations. This paper focuses on enzyme replacement therapy (ERT), cell- and gene-based therapies (including hematopoietic stem cell transplantation and gene therapy), inhibition of GAG synthesis, and some other newly developed therapeutic approaches. Perspectives on MPS therapies are also discussed.<\/jats:p>","DOI":"10.3390\/cimb48070671","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:11:57Z","timestamp":1782785517000},"page":"671","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Therapies for Mucopolysaccharidoses"],"prefix":"10.3390","volume":"48","author":[{"given":"Joanna","family":"Szmydtka","sequence":"first","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Ziemian","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Banaszak","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Ciesielska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6351-5730","authenticated-orcid":false,"given":"Jagoda","family":"\u0141adosz","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Maliszewska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Paszek","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Supro\u0144","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"\u015awi\u0119tochowska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Tkaczuk","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon","family":"Wojciechowski","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4042-7466","authenticated-orcid":false,"given":"Grzegorz","family":"W\u0119grzyn","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Biology, University of Gda\u0144sk, Wita Stwosza 59, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Leal, A.F., Benincore-Fl\u00f3rez, E., Rintz, E., Herre\u00f1o-Pach\u00f3n, A.M., Celik, B., Ago, Y., Alm\u00e9ciga-D\u00edaz, C.J., and Tomatsu, S. (2022). Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010477"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108507","DOI":"10.1016\/j.ymgme.2024.108507","article-title":"Causes of Death in Mucopolysaccharidoses","volume":"142","author":"Rintz","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Celik, B., Tomatsu, S.C., Tomatsu, S., and Khan, S.A. (2021). Epidemiology of Mucopolysaccharidoses Update. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020273"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cge.13583","article-title":"Genotype-phenotype Relationships in Mucopolysaccharidosis Type I (MPS I): Insights from the International MPS I Registry","volume":"96","author":"Clarke","year":"2019","journal-title":"Clin. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41419-018-0871-8","article-title":"Shutdown of ER-Associated Degradation Pathway Rescues Functions of Mutant Iduronate 2-Sulfatase Linked to Mucopolysaccharidosis Type II","volume":"9","author":"Osaki","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13052-018-0553-2","article-title":"Biochemical and Molecular Analysis in Mucopolysaccharidoses: What a Paediatrician Must Know","volume":"44","author":"Filocamo","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hampe, C.S., Yund, B.D., Orchard, P.J., Lund, T.C., Wesley, J., and McIvor, R.S. (2021). Differences in MPS I and MPS II Disease Manifestations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157888"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lipi\u0144ski, P., R\u00f3\u017cd\u017cy\u0144ska-\u015awi\u0105tkowska, A., Wi\u015bniewska, K., Rusecka, J., \u0141ugowska, A., \u017buber, Z., Jezela-Stanek, A., Cyske, Z., Gaffke, L., and Pierzynowska, K. (2025). Mucopolysaccharidoses\u2014What Clinicians Need to Know: A Clinical, Biochemical, and Molecular Overview. Biomolecules, 15.","DOI":"10.3390\/biom15101448"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hampe, C.S., Wesley, J., Lund, T.C., Orchard, P.J., Polgreen, L.E., Eisengart, J.B., McLoon, L.K., Cureoglu, S., Schachern, P., and McIvor, R.S. (2021). Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement. Biomolecules, 11.","DOI":"10.3390\/biom11020189"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/d41573-026-00055-z","article-title":"First-in-Class Blood\u2013Brain Barrier Shuttle Wins FDA Nod for Hunter Syndrome","volume":"25","author":"Mullard","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.pedneo.2022.10.001","article-title":"Current and New Therapies for Mucopolysaccharidoses","volume":"64","author":"Blair","year":"2023","journal-title":"Pediatr. Neonatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cyske, Z., Gaffke, L., Pierzynowska, K., and W\u0119grzyn, G. (2024). Mucopolysaccharidosis-Plus Syndrome: Is This a Type of Mucopolysaccharidosis or a Separate Kind of Metabolic Disease?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179570"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cyske, Z., Rintz, E., Narajczyk, M., \u015awi\u0105tek, N., Gaffke, L., Pierzynowska, K., and W\u0119grzyn, G. (2025). Cellular and Molecular Changes in Mucopolysaccharidosis-plus Syndrome Caused by a Homozygous c.599G > C (p.Arg200Pro) Variant of the VPS33A Gene. J. Appl. Genet.","DOI":"10.1007\/s13353-025-00997-x"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sawamoto, K., \u00c1lvarez Gonz\u00e1lez, J., Piechnik, M., Otero, F., Couce, M., Suzuki, Y., and Tomatsu, S. (2020). Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041517"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"D\u2019Avanzo, F., Zanetti, A., De Filippis, C., and Tomanin, R. (2021). Mucopolysaccharidosis Type VI, an Updated Overview of the Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413456"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108145","DOI":"10.1016\/j.ymgme.2024.108145","article-title":"Mucopolysaccharidosis Type VII (Sly Syndrome)\u2014What Do We Know?","volume":"141","author":"Grant","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199610033351405","article-title":"Clinical and Biochemical Manifestations of Hyaluronidase Deficiency","volume":"335","author":"Natowicz","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jmedgenet-2021-108061","article-title":"Novel Subtype of Mucopolysaccharidosis Caused by Arylsulfatase K (ARSK) Deficiency","volume":"59","author":"Verheyen","year":"2022","journal-title":"J. Med. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Vasilev, F., Sukhomyasova, A., and Otomo, T. (2020). Mucopolysaccharidosis-Plus Syndrome. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020421"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/cge.14002","article-title":"Homozygous Missense VPS16 Variant Is Associated with a Novel Disease, Resembling Mucopolysaccharidosis-plus Syndrome in Two Siblings","volume":"100","author":"Aytekin","year":"2021","journal-title":"Clin. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13376","DOI":"10.15252\/emmm.202013376","article-title":"Bi-allelic VPS16 Variants Limit HOPS\/CORVET Levels and Cause a Mucopolysaccharidosis-like Disease","volume":"13","author":"Sofou","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wi\u015bniewska, K., Wolski, J., \u017babi\u0144ska, M., Szulc, A., Gaffke, L., Pierzynowska, K., and W\u0119grzyn, G. (2024). Mucopolysaccharidosis Type IIIE: A Real Human Disease or a Diagnostic Pitfall?. Diagnostics, 14.","DOI":"10.3390\/diagnostics14161734"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s13353-022-00703-1","article-title":"Misdiagnosis in Mucopolysaccharidoses","volume":"63","author":"Wolski","year":"2022","journal-title":"J. Appl. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A Dose-Optimization Trial of Laronidase (Aldurazyme\u00ae) in Patients with Mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2022.07.016","article-title":"Long-Term Open-Label Extension Study of the Safety and Efficacy of Intrathecal Idursulfase-IT in Patients with Neuronopathic Mucopolysaccharidosis II","volume":"137","author":"Muenzer","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","article-title":"Enzyme Replacement Therapy for Mucopolysaccharidosis VI: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase (Recombinant Human Arylsulfatase B or rhASB) and Follow-on, Open-Label Extension Study","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-Term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13023-017-0634-0","article-title":"Clinical Outcomes in a Subpopulation of Adults with Morquio A Syndrome: Results from a Long-Term Extension Study of Elosulfase Alfa","volume":"12","author":"Hughes","year":"2017","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jimd.12316","article-title":"Novel Therapies for Mucopolysaccharidosis Type III","volume":"44","author":"Davison","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13052-024-01769-9","article-title":"The Diagnosis and Management of Mucopolysaccharidosis Type II","volume":"50","author":"Mao","year":"2024","journal-title":"Ital. J. Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Giugliani, R., Martins, A.M., Okuyama, T., Eto, Y., Sakai, N., Nakamura, K., Morimoto, H., Minami, K., Yamamoto, T., and Yamaoka, M. (2021). Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci., 22.","DOI":"10.20944\/preprints202109.0192.v1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-Sulfatase with Anti-Human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1\/2 Trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","article-title":"Iduronate-2-Sulfatase Fused with Anti-hTfR Antibody, Pabinafusp Alfa, for MPS-II: A Phase 2 Trial in Brazil","volume":"29","author":"Giugliani","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa2508681","article-title":"An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II","volume":"394","author":"Muenzer","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jimd.12626","article-title":"Gene Therapies for Mucopolysaccharidoses","volume":"47","author":"Rossi","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wood, S.R., and Bigger, B.W. (2022). Delivering Gene Therapy for Mucopolysaccharide Diseases. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.965089"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Santos, J.I., Gon\u00e7alves, M., Almeida, M.B., Rocha, H., Duarte, A.J., Matos, L., Moreira, L.V., Encarna\u00e7\u00e3o, M., Gaspar, P., and Prata, M.J. (2025). mRNA Degradation as a Therapeutic Solution for Mucopolysaccharidosis Type IIIC: Use of Antisense Oligonucleotides to Promote Downregulation of Heparan Sulfate Synthesis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031273"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1093\/nar\/gkab194","article-title":"Effect of Small Molecule eRF3 Degraders on Premature Termination Codon Readthrough","volume":"49","author":"Balgi","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Piechnik, M., Sawamoto, K., Ohnishi, H., Kawamoto, N., Ago, Y., and Tomatsu, S. (2020). Evading the AAV Immune Response in Mucopolysaccharidoses. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103433"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13820","DOI":"10.1039\/D4NR01300J","article-title":"Chemical Approaches to Probe and Engineer AAV Vectors","volume":"16","author":"Pham","year":"2024","journal-title":"Nanoscale"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13023-020-01644-w","article-title":"Long Term Disease Burden Post-Transplantation: Three Decades of Observations in 25 Hurler Patients Successfully Treated with Hematopoietic Stem Cell Transplantation (HSCT)","volume":"16","author":"Guffon","year":"2021","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101367","DOI":"10.1016\/j.omtm.2024.101367","article-title":"Human iPSC-Derived Neural Stem Cells Engraft and Improve Pathophysiology of MPS I Mice","volume":"32","author":"Calhoun","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jha2.1056","article-title":"Incidence and Risk Factors of Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis in a Nationwide Pediatric Cohort. A Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy","volume":"5","author":"Danhardt","year":"2024","journal-title":"eJHaem"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/bloodadvances.2022007212","article-title":"Hematopoietic Stem Cell Transplant for Hurler Syndrome: Does Using Bone Marrow or Umbilical Cord Blood Make a Difference?","volume":"6","author":"Orchard","year":"2022","journal-title":"Blood Adv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"91.e1","DOI":"10.1016\/j.bbmt.2020.08.033","article-title":"Outcome After Cord Blood Transplantation Using Busulfan Pharmacokinetics-Targeted Myeloablative Conditioning for Hurler Syndrome","volume":"27","author":"Lum","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"157.e1","DOI":"10.1016\/j.jtct.2021.11.023","article-title":"Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report","volume":"28","author":"Wadhwa","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41409-025-02512-6","article-title":"Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism\u2014A Retrospective Analysis on Behalf of the Pediatric Disease Working Party from the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy","volume":"60","author":"Rodrigues","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12185-024-03810-3","article-title":"Allogeneic Stem Cell Transplantation for Inherited Metabolic Disorders: 35 Years\u2019 Experience at a Single Institution","volume":"120","author":"Yabe","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_49","first-page":"100881","article-title":"Efficacy of Early Haematopoietic Stem Cell Transplantation versus Enzyme Replacement Therapy on Neurological Progression in Severe Hunter Syndrome: Case Report of Siblings and Literature Review","volume":"32","author":"Sreekantam","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41409-024-02439-4","article-title":"Hematopoietic Stem Cell Transplantation in Children with Mucopolysaccharidosis IVA: Single Center Experience","volume":"60","author":"Yalcin","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3345\/cep.2024.02033","article-title":"Hematopoietic Stem Cell Transplantation in Pediatric Patients with Type VI Mucopolysaccharidosis","volume":"68","author":"Uygun","year":"2025","journal-title":"Clin. Exp. Pediatr."},{"key":"ref_52","first-page":"26330040231154283","article-title":"Successful Combined Umbilical Cord Blood and Bone Marrow Transplantation from an HLA-Matched Sibling for MPS VI: A Case Report","volume":"4","author":"Haria","year":"2023","journal-title":"Ther. Adv. Rare Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"71.E1","DOI":"10.1016\/j.jhsa.2025.09.018","article-title":"Effect of Early Hematopoietic Stem Cell Transplantation on Carpal Tunnel Syndrome Surgery in Patients with Hurler Syndrome","volume":"51","author":"Reiners","year":"2026","journal-title":"J. Hand Surg."},{"key":"ref_54","first-page":"101254","article-title":"Case Report of Neuronopathic Mucopolysaccharidosis Type II: Early Intracerebroventricular Enzyme Replacement Therapy and Hematopoietic Cell Transplantation with Developmental Outcomes up to 5 Years of Age","volume":"45","author":"Ikari","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_55","first-page":"703.e1","article-title":"Allogeneic Hematopoietic Cell Transplantation for Morquio A Syndrome: An International Retrospective Study","volume":"32","author":"Kharbanda","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101127","DOI":"10.1016\/j.omtm.2023.101127","article-title":"Sustained Long-Term Disease Correction in a Murine Model of MPSII Following Stem Cell Gene Therapy","volume":"31","author":"Ellison","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101514","DOI":"10.1016\/j.omtm.2025.101514","article-title":"In Vivo Direct Lentiviral Gene Therapy Improves Disease Pathology in a Mucopolysaccharidosis IVA Murine Model","volume":"33","author":"Celik","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"101153","DOI":"10.1016\/j.omtm.2023.101153","article-title":"Iron Oxide-Coupled CRISPR-nCas9-Based Genome Editing Assessment in Mucopolysaccharidosis IVA Mice","volume":"31","author":"Leal","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101313","DOI":"10.1016\/j.omtm.2024.101313","article-title":"A GLB1 Transgene with Enhanced Therapeutic Potential for the Preclinical Development of Ex-Vivo Gene Therapy to Treat Mucopolysaccharidosis Type IVB","volume":"32","author":"Crippa","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1016\/j.ymthe.2024.09.033","article-title":"Engineering Memory T Cells as a Platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage Disorders","volume":"32","author":"Kleinboehl","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ymthe.2024.01.034","article-title":"An Empowered, Clinically Viable Hematopoietic Stem Cell Gene Therapy for the Treatment of Multisystemic Mucopolysaccharidosis Type II","volume":"32","author":"Das","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41423-021-00640-9","article-title":"Which Is Better, HLA-Matched Sibling or Haploidentical Transplantation?","volume":"18","author":"Zheng","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymthe.2025.09.042","article-title":"Non-Neurological, Non-Skeletal Outcomes after Hematopoietic Stem and Progenitor Cell-Gene Therapy (OTL-203) for Hurler Syndrome","volume":"34","author":"Tucci","year":"2026","journal-title":"Mol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2025-384","article-title":"Ex-Vivo Modification of Autologous CD34+ HSPCs Using a CD11B-Directed Lentiviral Vector Encoding APOEII-Tagged Human IDS Leads to Supraphysiological Enzyme Activity and Early Biochemical Correction of Neuronopathic Mucopolysaccharidosis Type II Patients","volume":"146","author":"Jeffreys","year":"2025","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2022-168672","article-title":"Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA","volume":"140","author":"Wynn","year":"2022","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1089\/hum.2024.094","article-title":"Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model","volume":"35","author":"Celik","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Nidhi, F., and Tomatsu, S. (2025). Integrase-Deficient Lentiviral Vector as a Platform for Efficient CRISPR\/Cas9-Mediated Gene Editing for Mucopolysaccharidosis IVA. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146616"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15045","DOI":"10.1038\/s41598-022-19407-x","article-title":"Delivery and Assessment of a CRISPR\/nCas9-Based Genome Editing System on In Vitro Models of Mucopolysaccharidoses IVA Assisted by Magnetite-Based Nanoparticles","volume":"12","author":"Leal","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ymthe.2024.04.001","article-title":"TALEN-Mediated Intron Editing of HSPCs Enables Transgene Expression Restricted to the Myeloid Lineage","volume":"32","author":"Seclen","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s11427-024-2915-x","article-title":"CRISPR\/Cas9-Mediated Promoterless Gene Targeting Reduces Lysosome Storage in MPS VII Mice","volume":"68","author":"Shan","year":"2025","journal-title":"Sci. China Life Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jpeds.2008.11.005","article-title":"Improved Metabolic Correction in Patients with Lysosomal Storage Disease Treated with Hematopoietic Stem Cell Transplant Compared with Enzyme Replacement Therapy","volume":"154","author":"Wynn","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ljungman, P., Snydman, D., and Boeckh, M. (2016). Risks and Epidemiology of Infections After Hematopoietic Stem Cell Transplantation. Transplant Infections, Springer International Publishing.","DOI":"10.1007\/978-3-319-28797-3"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Petrova, I.O., and Smirnikhina, S.A. (2025). Ex Vivo Gene and Cell Therapy in Hematopoietic Stem Cells. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311466"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41409-022-01886-1","article-title":"Long Term Follow-up after Haematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Type I-H: A Retrospective Study of 51 Patients","volume":"58","author":"Gardin","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Poletti, V., and Mavilio, F. (2021). Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases. Viruses, 13.","DOI":"10.3390\/v13081526"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ago, Y., Rintz, E., Musini, K., Ma, Z., and Tomatsu, S. (2024). Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021113"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"104510","DOI":"10.1016\/j.drudis.2025.104510","article-title":"Advancing Ex Vivo Gene Therapy: The Role of Lentiviral Vectors and Organizational Collaboration","volume":"30","author":"Nishida","year":"2025","journal-title":"Drug Discov. Today"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcyt.2024.09.001","article-title":"The Role of the Conditioning Regimen for Autologous and Ex Vivo Genetically Modified Hematopoietic Stem Cell-Based Therapies: Recommendations from the ISCT Stem Cell Engineering Committee","volume":"27","author":"Oved","year":"2025","journal-title":"Cytotherapy"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"MPS Consensus Programme Steering Committee, MPS Consensus Programme Co-Chairs, Akyol, M.U., Alden, T.D., Amartino, H., Ashworth, J., Belani, K., Berger, K.I., Borgo, A., and Braunlin, E. (2019). Recommendations for the Management of MPS IVA: Systematic Evidence- and Consensus-Based Guidance. Orphanet. J. Rare Dis., 14, 137.","DOI":"10.1186\/s13023-019-1074-9"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"145527","DOI":"10.1016\/j.gene.2021.145527","article-title":"Evaluation of HIV\u20131 Derived Lentiviral Vectors as Transductors of Mucopolysaccharidosis Type IV a Fibroblasts","volume":"780","author":"Barbosa","year":"2021","journal-title":"Gene"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Celik, B., Saikia, S., Khan, S., Musini, K.S., and Tomatsu, S. (2025). Collagen Type II-Targeting Lentiviral Gene Therapy for Mucopolysaccharidosis IVA. CIMB, 48.","DOI":"10.3390\/cimb48010042"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13052-018-0565-y","article-title":"Gene Therapy for Mucopolysaccharidoses: In Vivo and Ex Vivo Approaches","volume":"44","author":"Fraldi","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_84","first-page":"1","article-title":"Liver-Directed Adeno-Associated Virus\u2013Mediated Gene Therapy for Mucopolysaccharidosis Type VI","volume":"1","author":"Ferla","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/acn3.51772","article-title":"Focal Lesions Following Intracerebral Gene Therapy for Mucopolysaccharidosis IIIA","volume":"10","author":"Bugiani","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Gougeon, M.-L., Poirier-Beaudouin, B., Ausseil, J., Z\u00e9rah, M., Artaud, C., Heard, J.-M., Deiva, K., and Tardieu, M. (2021). Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children with Mucopolysaccharidosis Type IIIB Syndrome. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.655478"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1089\/hum.2021.135","article-title":"Intracerebral Gene Therapy in Four Children with Sanfilippo B Syndrome: 5.5-Year Follow-Up Results","volume":"32","author":"Deiva","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_88","first-page":"100956","article-title":"Non-Invasive Intravenous Administration of AAV9 Transducing Iduronate Sulfatase Leads to Global Metabolic Correction and Prevention of Neurologic Deficits in a Mouse Model of Hunter Syndrome","volume":"34","author":"Laoharawee","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1038\/s41467-021-25697-y","article-title":"Treatment of Skeletal and Non-Skeletal Alterations of Mucopolysaccharidosis Type IVA by AAV-Mediated Gene Therapy","volume":"12","author":"Bertolin","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Rintz, E., Herre\u00f1o-Pach\u00f3n, A.M., Celik, B., Nidhi, F., Khan, S., Benincore-Fl\u00f3rez, E., and Tomatsu, S. (2023). Bone Growth Induction in Mucopolysaccharidosis IVA Mouse. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24129890"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/hmg\/ddac209","article-title":"Disease Correction in Mucopolysaccharidosis Type IIIB Mice by Intraparenchymal or Cisternal Delivery of a Capsid Modified AAV8 Codon-Optimized NAGLU Vector","volume":"32","author":"Rouse","year":"2023","journal-title":"Hum. Mol. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.omtm.2022.04.010","article-title":"Liver-Directed Gene Therapy Corrects Neurologic Disease in a Murine Model of Mucopolysaccharidosis Type I-Hurler","volume":"25","author":"Jin","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"101369","DOI":"10.1016\/j.omtm.2024.101369","article-title":"Intrathecal or Intravenous AAV9-IDUA\/RGX-111 at Minimal Effective Dose Prevents Cardiac, Skeletal and Neurologic Manifestations of Murine MPS I","volume":"32","author":"Belur","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/hum.2022.162","article-title":"Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction","volume":"34","author":"Laoharawee","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.omtm.2023.03.014","article-title":"Gene Therapy for Cross-Correction of Somatic Organs and the CNS in Mucopolysaccharidosis II in Rodents and Non-Human Primates","volume":"29","author":"Chen","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1016\/j.omtm.2024.101201","article-title":"Comparative Dose Effectiveness of Intravenous and Intrathecal AAV9.CB7.hIDS, RGX-121, in Mucopolysaccharidosis Type II Mice","volume":"32","author":"Smith","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Piechnik, M., Amendum, P.C., Sawamoto, K., Stapleton, M., Khan, S., Fnu, N., \u00c1lvarez, V., Pachon, A.M.H., Danos, O., and Bruder, J.T. (2022). Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012693"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1016\/j.ymthe.2024.09.030","article-title":"Anti-Amyloid Treatment Is Broadly Effective in Neuronopathic Mucopolysaccharidoses and Synergizes with Gene Therapy in MPS-IIIA","volume":"32","author":"Giaccio","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/hum.2024.096","article-title":"Adeno-Associated Virus Gene Transfer Ameliorates Progression of Skeletal Lesions in Mucopolysaccharidosis IVA Mice","volume":"35","author":"Sawamoto","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_100","first-page":"130","article-title":"Intravenous Delivery of a Gene Therapy Vector That Expresses an Antitransferrin Receptor 1 Nanobody-I2S Fusion Protein Rescued Central Nervous System Lysosomal Burden in Mucopolysaccharidosis II Mice","volume":"37","author":"Ruangsiriluk","year":"2026","journal-title":"Hum. Gene Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e00741","DOI":"10.1016\/j.neurot.2025.e00741","article-title":"Rescue of Neurologic Disease in Mucopolysaccharidosis Type II Mice via AAV-Mediated Liver Delivery of Brain-Penetrating Iduronate-2-Sulfatase","volume":"22","author":"Jin","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e12464","DOI":"10.1002\/jev2.12464","article-title":"AAV Gene Replacement Therapy for Treating MPS IIIC: Facilitating Bystander Effects via EV-mRNA Cargo","volume":"13","author":"Bobo","year":"2024","journal-title":"J. Extracell. Vesicle"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12967-023-04208-1","article-title":"Intraparenchymal Convection Enhanced Delivery of AAV in Sheep to Treat Mucopolysaccharidosis IIIC","volume":"21","author":"Forte","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e14919","DOI":"10.1111\/cns.14919","article-title":"Evaluation of Neuroretina Following i.v. or Intra-CSF AAV9 Gene Replacement in Mice with MPS IIIA, a Childhood Dementia","volume":"30","author":"Beard","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Belur, L.R., Romero, M., Lee, J., Podetz-Pedersen, K.M., Nan, Z., Riedl, M.S., Vulchanova, L., Kitto, K.F., Fairbanks, C.A., and Kozarsky, K.F. (2021). Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I. Front. Mol. Neurosci., 14.","DOI":"10.3389\/fnmol.2021.618360"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41434-020-00206-w","article-title":"Site-Specific Modifications to AAV8 Capsid Yields Enhanced Brain Transduction in the Neonatal MPS IIIB Mouse","volume":"28","author":"Gilkes","year":"2021","journal-title":"Gene Ther."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Khan, S.A., Benincore-Florez, E., Nidhi, F., \u00c1lvarez, J.V., Holder, D.A., and Tomatsu, S. (2025). Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA. CIMB, 47.","DOI":"10.3390\/cimb47110900"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Gilger, B.C., Song, L., Hasegawa, T., Salmon, J.H., Bower, J.J., Vridhachalam, N., Collins, E., Roberts, D., Bagel, J., and Molony, C. (2025). Adeno-Associated Vector Corneal Gene Therapy Reverses Corneal Clouding in a Feline Model of Mucopolysaccharidosis VI. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0338370"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"12716","DOI":"10.1038\/s41598-023-39939-0","article-title":"Mapping Brain Networks in MPS I Mice and Their Restoration Following Gene Therapy","volume":"13","author":"Zhu","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.omtm.2021.09.017","article-title":"Seven-Year Follow-up of Durability and Safety of AAV CNS Gene Therapy for a Lysosomal Storage Disorder in a Large Animal","volume":"23","author":"Haurigot","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"102211","DOI":"10.1016\/j.omtn.2024.102211","article-title":"Adeno-Associated Virus-Based Gene Therapy Delivering Combinations of Two Growth-Associated Genes to MPS IVA Mice","volume":"35","author":"Rintz","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7419017","DOI":"10.1155\/2023\/7419017","article-title":"Intra-Articular AAV9 \u03b1-l-Iduronidase Gene Replacement in the Canine Model of Mucopolysaccharidosis Type I","volume":"2023","author":"Wang","year":"2023","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"101447","DOI":"10.1016\/j.omtm.2025.101447","article-title":"Evaluation of AAV Vectors with Tissue-Specific or Ubiquitous Promoters in a Mouse Model of Mucopolysaccharidosis Type IVA","volume":"33","author":"Khan","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1089\/hum.2020.253","article-title":"Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease","volume":"32","author":"Saville","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtos.2024.01.002","article-title":"Self-Complementary AAV Vector Therapy for Treating Corneal Cloudiness of Mucopolysaccharidosis Type VII (MPS VII)","volume":"32","author":"Venkatakrishnan","year":"2024","journal-title":"Ocul. Surf."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/BTT.S326422","article-title":"Mechanism and Applications of CRISPR\/Cas-9-Mediated Genome Editing","volume":"15","author":"Mengstie","year":"2021","journal-title":"BTT"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41434-022-00344-3","article-title":"Efficient CRISPR\/Cas9 Nickase-Mediated Genome Editing in an In Vitro Model of Mucopolysaccharidosis IVA","volume":"30","author":"Leal","year":"2023","journal-title":"Gene Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e3410","DOI":"10.1002\/jgm.3410","article-title":"Brain and Visceral Gene Editing of Mucopolysaccharidosis I Mice by Nasal Delivery of the CRISPR\/Cas9 System","volume":"24","author":"Vera","year":"2022","journal-title":"J. Gene Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2018.08.031","article-title":"In Vivo Genome Editing of Mucopolysaccharidosis I Mice Using the CRISPR\/Cas9 System","volume":"288","author":"Schuh","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1038\/s41467-021-26518-y","article-title":"Self-Inactivating, All-in-One AAV Vectors for Precision Cas9 Genome Editing via Homology-Directed Repair In Vivo","volume":"12","author":"Ibraheim","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-Human In Vivo Genome Editing via AAV-Zinc-Finger Nucleases for Mucopolysaccharidosis I\/II and Hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1038\/s41467-021-24443-8","article-title":"In Utero Adenine Base Editing Corrects Multi-Organ Pathology in a Lethal Lysosomal Storage Disease","volume":"12","author":"Bose","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime Editing for Precise and Highly Versatile Genome Manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the Art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13059-023-03086-6","article-title":"Utilizing AAV-Mediated LEAPER 2.0 for Programmable RNA Editing in Non-Human Primates and Nonsense Mutation Correction in Humanized Hurler Syndrome Mice","volume":"24","author":"Yi","year":"2023","journal-title":"Genome Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41587-021-01180-3","article-title":"Engineered Circular ADAR-Recruiting RNAs Increase the Efficiency and Fidelity of RNA Editing In Vitro and In Vivo","volume":"40","author":"Yi","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00005-012-0195-9","article-title":"Putative Biological Mechanisms of Efficiency of Substrate Reduction Therapies for Mucopolysaccharidoses","volume":"60","year":"2012","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4103\/ijo.IJO_425_22","article-title":"Mucopolysaccharidosis: A Broad Review","volume":"70","author":"Nagpal","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Horgan, C., Jones, S.A., Bigger, B.W., and Wynn, R. (2022). Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094854"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Coutinho, M., Santos, J., and Alves, S. (2016). Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071065"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF03195237","article-title":"Substrate Deprivation Therapy: A New Hope for Patients Suffering from Neuronopathic Forms of Inherited Lysosomal Storage Diseases","volume":"48","year":"2007","journal-title":"J. Appl. Genet."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.2174\/138920111798376932","article-title":"Substrate Reduction Therapies for Mucopolysaccharidoses","volume":"12","author":"Piotrowska","year":"2011","journal-title":"CPB"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/iub.1007","article-title":"Gene Expression-targeted Isoflavone Therapy","volume":"64","year":"2012","journal-title":"IUBMB Life"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1423-0127-16-26","article-title":"Genistein-Mediated Inhibition of Glycosaminoglycan Synthesis, Which Corrects Storage in Cells of Patients Suffering from Mucopolysaccharidoses, Acts by Influencing an Epidermal Growth Factor-Dependent Pathway","volume":"16","author":"Piotrowska","year":"2009","journal-title":"J. Biomed. Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12079-019-00527-5","article-title":"Mechanisms of PAR-1 Mediated Kinase Receptor Transactivation: Smad Linker Region Phosphorylation","volume":"13","author":"Kamato","year":"2019","journal-title":"J. Cell Commun. Signal."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"17054","DOI":"10.1074\/jbc.M114.555300","article-title":"The Phytoestrogen Genistein Modulates Lysosomal Metabolism and Transcription Factor EB (TFEB) Activation","volume":"289","author":"Moskot","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/jimd.12407","article-title":"High Dose Genistein in Sanfilippo Syndrome: A Randomised Controlled Trial","volume":"44","author":"Ghosh","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13311-022-01323-7","article-title":"Activities of (Poly)Phenolic Antioxidants and Other Natural Autophagy Modulators in the Treatment of Sanfilippo Disease: Remarkable Efficacy of Resveratrol in Cellular and Animal Models","volume":"20","author":"Rintz","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"W\u0119sierska, M., Nowicka, W., Kloska, A., Jak\u00f3bkiewicz-Banecka, J., and Malinowska, M. (2022). Murine Fibroblasts and Primary Hepatocytes as Tools When Studying the Efficacy of Potential Therapies for Mucopolysaccharidosis Type I. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010534"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.ejhg.5201623","article-title":"Genistein-Mediated Inhibition of Glycosaminoglycan Synthesis as a Basis for Gene Expression-Targeted Isoflavone Therapy for Mucopolysaccharidoses","volume":"14","author":"Piotrowska","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10545-009-9029-2","article-title":"Storage Correction in Cells of Patients Suffering from Mucopolysaccharidoses Types IIIA and VII after Treatment with Genistein and Other Isoflavones","volume":"33","author":"Arfi","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_144","first-page":"1","article-title":"Cyclodextrin Encapsulation of Daidzein and Genistein by Grinding: Implication on the Glycosaminoglycan Accumulation in Mucopolysaccharidosis Type II and III Fibroblasts","volume":"35","author":"Jablan","year":"2018","journal-title":"J. Microencapsul."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11011-011-9233-2","article-title":"Effects of Flavonoids on Glycosaminoglycan Synthesis: Implications for Substrate Reduction Therapy in Sanfilippo Disease and Other Mucopolysaccharidoses","volume":"26","author":"Kloska","year":"2011","journal-title":"Metab. Brain Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"cwae025","DOI":"10.1093\/glycob\/cwae025","article-title":"Inhibitors of Dermatan Sulfate Epimerase 1 Decreased Accumulation of Glycosaminoglycans in Mucopolysaccharidosis Type I Fibroblasts","volume":"34","author":"Maccarana","year":"2024","journal-title":"Glycobiology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1476-5381.2009.00565.x","article-title":"Genistein Reduces Glycosaminoglycan Levels in a Mouse Model of Mucopolysaccharidosis Type II","volume":"159","author":"Friso","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Malinowska, M., Wilkinson, F.L., Langford-Smith, K.J., Langford-Smith, A., Brown, J.R., Crawford, B.E., Vanier, M.T., Grynkiewicz, G., Wynn, R.F., and Wraith, J.E. (2010). Genistein Improves Neuropathology and Corrects Behaviour in a Mouse Model of Neurodegenerative Metabolic Disease. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014192"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.curtheres.2008.04.002","article-title":"Genistin-Rich Soy Isoflavone Extract in Substrate Reduction Therapy for Sanfilippo Syndrome: An Open-Label, Pilot Study in 10 Pediatric Patients","volume":"69","author":"Piotrowska","year":"2008","journal-title":"Curr. Ther. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ymgme.2013.06.012","article-title":"High Dose Genistein Aglycone Therapy Is Safe in Patients with Mucopolysaccharidoses Involving the Central Nervous System","volume":"109","author":"Kim","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/ajmg.a.34146","article-title":"Improvement in the Range of Joint Motion in Seven Patients with Mucopolysaccharidosis Type II during Experimental Gene Expression-targeted Isoflavone Therapy (GET IT)","volume":"155","author":"Marucha","year":"2011","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s10545-014-9703-x","article-title":"Genistein Increases Glycosaminoglycan Levels in Mucopolysaccharidosis Type I Cell Models","volume":"37","author":"Kingma","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00335-025-10176-2","article-title":"The Use of Genistein and Ambroxol May Be an Effective Approach in Correcting Cellular Dysfunctions of Mucopolysaccharidosis-plus Syndrome","volume":"37","author":"Cyske","year":"2026","journal-title":"Mamm. Genome"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s12276-026-01643-0","article-title":"TFEB, FOXO3 and TLR4 in Resveratrol-Induced Autophagy in a Mucopolysaccharidosis IIIB Mouse Model","volume":"58","author":"Rintz","year":"2026","journal-title":"Exp. Mol. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","article-title":"Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1\u03b1","volume":"127","author":"Lagouge","year":"2006","journal-title":"Cell"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","article-title":"Bioavailability of Resveratrol","volume":"1215","author":"Walle","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e20211860","DOI":"10.1084\/jem.20211860","article-title":"Glucosamine Amends CNS Pathology in Mucopolysaccharidosis IIIC Mouse Expressing Misfolded HGSNAT","volume":"219","author":"Pan","year":"2022","journal-title":"J. Exp. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"109112","DOI":"10.1016\/j.ymgme.2025.109112","article-title":"Substrate Reduction Using a Glucosamine Analogue in Drosophila Melanogaster and Mouse Models of Sanfilippo Syndrome","volume":"145","author":"Tan","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e202400081","DOI":"10.1002\/cbic.202400081","article-title":"Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB","volume":"25","author":"Losada","year":"2024","journal-title":"ChemBioChem"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1021\/acs.jmedchem.2c01617","article-title":"N-Substituted l-Iminosugars for the Treatment of Sanfilippo Type B Syndrome","volume":"66","author":"Esposito","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e12816","DOI":"10.1002\/jimd.12816","article-title":"Development of a Novel Tool for Individual Treatment Trials in Mucopolysaccharidosis","volume":"48","author":"Wiesinger","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ymgme.2021.07.008","article-title":"MPS VI Associated Ocular Phenotypes in an MPS VI Murine Model and the Therapeutic Effects of Odiparcil Treatment","volume":"135","author":"Entchev","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3934\/biophy.2017.3.337","article-title":"Mechanisms and Applications of the Anti-Inflammatory Effects of Photobiomodulation","volume":"4","author":"Hamblin","year":"2017","journal-title":"AIMS Biophys."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10571-020-01016-9","article-title":"The Molecular Mechanisms of Action of Photobiomodulation Against Neurodegenerative Diseases: A Systematic Review","volume":"42","author":"Bathini","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1111\/jnc.16145","article-title":"Photobiomodulation in the Infrared Spectrum Reverses the Expansion of Circulating Natural Killer Cells and Brain Microglial Activation in Sanfilippo Mice","volume":"168","author":"Lau","year":"2024","journal-title":"J. Neurochem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"109754","DOI":"10.1016\/j.abb.2023.109754","article-title":"Therapeutic Potential of Lithium Chloride and Valproic Acid against Neuronopathic Types of Mucopolysaccharidoses through Induction of the Autophagy Process","volume":"747","author":"Gaffke","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Cyske, Z., Radzanowska-Alenowicz, E., Rintz, E., Gaffke, L., and Pierzynowska, K. (2025). The Rare Disease Burden: A Multidimensional Challenge. Acta Biochim. Pol., 72.","DOI":"10.3389\/abp.2025.14777"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2022353","DOI":"10.1080\/20016689.2021.2022353","article-title":"Pricing Zolgensma\u2014The World\u2019s Most Expensive Drug","volume":"10","author":"Nuijten","year":"2022","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13023-022-02285-x","article-title":"The Landscape of Mucopolysaccharidosis in Southern and Eastern European Countries: A Survey from 19 Specialistic Centers","volume":"17","author":"Barisic","year":"2022","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/7\/671\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:15:12Z","timestamp":1783656912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/7\/671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":170,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cimb48070671"],"URL":"https:\/\/doi.org\/10.3390\/cimb48070671","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}